Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

2026-02-02
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

2026-01-29
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

2026-01-26
Adma Biologics (ADMA) concluded the recent trading session at $16.96, signifying a +1.37% move from its prior day's close.

ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?

2026-01-22
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.

High Growth US Tech Stocks To Watch In January 2026

2026-01-21
As the U.S. market grapples with heightened geopolitical tensions and the threat of new tariffs, major indices like the Nasdaq and S&P 500 have experienced significant declines, reflecting broader market unease. Amidst this volatility, investors often seek stocks with strong fundamentals and innovative potential that can navigate such uncertain environments effectively.

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

2026-01-20
Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.

ADMA Biologics, Inc. (ADMA): A Bull Case Theory

2026-01-14
We came across a bullish thesis on ADMA Biologics, Inc. on Stockmindsweb’s YouTube Channel. In this article, we will summarize the bulls’ thesis on ADMA. ADMA Biologics, Inc.’s share was trading at $17.70 as of January 13th. ADMA’s trailing and forward P/E were 20.58 and 28.99 respectively according to Yahoo Finance. ADMA Biologics is positioned as a […]

ADMA Biologics: Business Update And My Price Target

2026-01-14

Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

2026-01-13
In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.

ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook

2026-01-13
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.